NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.
Data on the number of items of cannabis-based medicines dispensed in NHS primary care in England from December 2018 to January 2019 has been published by the NHS Business Services Authority. Such data is published three months in arrears, and we expect information for February 2019 to be published shortly.
The published data shows that the following number of items of Nabilone and Sativex (two cannabis-based medicines) were dispensed from December 2018 to January 2019: